ClinicalTrials.gg
CompletedNCT04513522CheckMate 7C9Updated Jul 11, 2025Results posted

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

A Phase 4 interventional study of Nivolumab and Ipilimumab in Kidney Neoplasms, sponsored by Bristol-Myers Squibb. Completed at 11 sites in India. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing nivolumab in Kidney Neoplasms — 4 open to participants now, 7 under way, 2 of them phase 3. Nivolumab · Kidney Neoplasms.

Enrollment
5th of 19
101 · median 50
Started
2020
with 3 others
Phase 4
4 of 19
2 open now
Registered
13th of 19
by date
Lead sponsor
5 of 19
Bristol-Myers Squibb

Among the 19 studies testing nivolumab in Kidney Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2020, is one of 4 in phase 4, and was the 13th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

4 of the 19 studies testing nivolumab in Kidney Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nivolumab in Kidney Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC (mRCC) in India.

03

Conditions studied

  • Kidney Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of renal cell carcinoma (RCC) with clear cell component including participants who may have sarcomatoid features
  • Qualifies as intermediate or poor risk by meeting at least one of the prognostic factors as per the International RCC Database Consortium (IMDC) criteria
  • Indian participants with Indian ethnicity living in India
  • No prior systemic therapy for RCC
  • lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per (RECIST) 1.1 criteria

Exclusion criteria

Exclusion Criteria:

  • Participants with active, untreated, symptomatic central nervous system (CNS)
  • Major surgery less than 28 days prior to the first dose of study treatment
  • Participants with an disease, or any other condition, requiring systemic treatment with either or other medications

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Nivolumab + ipilimumab

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: BMS-734016, Yervoy

06

What researchers measure

Primary outcomes

  1. Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE)

    IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues, including diarrhea/colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash, and endocrine (adrenal insufficiency, hypophysitis, hypothyroidism/thyroiditis, hyperthyroidism, and diabetes mellitus). IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grade 3 to 4 and Grade 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose until 100 days after the last dose or for a maximum of 52 weeks from the date of the first on-study dose of nivolumab, whichever occurs earlier.

Secondary outcomes

  1. Time to Onset of High Grade Immune-Mediated Adverse Event (IMAE)

    Time to onset is defined as the time between the day of the first dose of study treatment and the onset date of the earliest AE (Grades 3-5) in this category. All IMAEs that occurred between first dose and 100 days past last dose are recorded. IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues. IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose until onset of IMAE (up to approximately 15 months)

  2. Time to Resolution of High Grade Immune-Mediated Adverse Event (IMAE)

    Time to resolution of IMAEs is defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered AEs experienced by the participant in this category per adverse event criteria category. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known alive date. Improvement to the grade at baseline implies that all different events in the clustered adverse event should at least have improved to the corresponding (i.e. with same preferred term) baseline grade. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose until resolution of IMAE (up to approximately 15 months)

  3. The Number of Participants Who Received Immune-Modulating Medication

    Immune modulating medications are medications entered on an immune modulating medication form or available from the most current pre-defined list of immune modulating medications. This list is revisited whenever UMC WHO releases a new version and updated accordingly.

    Time frame: From first dose up to 100 days after last dose (up to approximately 15 months)

  4. Objective Response Rate (ORR)

    Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose up to 100 days after last dose (up to approximately 15 months)

  5. Time to Response (TTR)

    TTR is defined as the time from the date of first dose to the date of the first confirmed documented response (CR or PR). For the non-responders, TTR was censored at the maximum time of response + 1 day of all participants. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of CR or PR (up to approximately 15 months)

  6. Duration of Response (DoR)

    Duration of Response (DOR) is defined as the time between the date of first documented response (CR or PR) that was subsequently confirmed to the date of the first documented progression as determined using RECIST 1.1, or death due to any cause, whichever occurs first. For participants who neither progress nor die, the duration of response will be censored on the date of their last evaluable tumor assessment. For participants who start subsequent therapy before progression or die, the duration of response will be censored on the date of their last evaluable tumor assessment conducted on or prior to the initiation of the subsequent therapy. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Analysis based on Kaplan Meier estimates.

    Time frame: From first documented response (CR or PR) up to first documented progression or death due to any cause, whichever occurs first (up to approximately 3 years)

07

Results

Posted Jul 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + Ipilimumab
Started101
Completed36
Not completed65
Withdrew: Other reasons1
Withdrew: Adverse event unrelated to study drug9
Withdrew: Study drug toxicity14
Withdrew: Disease progression39
Withdrew: Participants withdrew consent2

Outcome measures

PrimaryTotal Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE)

IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues, including diarrhea/colitis, hepatitis, pneumonitis, nephritis and renal dysfunction, rash, and endocrine (adrenal insufficiency, hypophysitis, hypothyroidism/thyroiditis, hyperthyroidism, and diabetes mellitus). IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grade 3 to 4 and Grade 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose until 100 days after the last dose or for a maximum of 52 weeks from the date of the first on-study dose of nivolumab, whichever occurs earlier.
Reported as:
Count of participants · Participants
Total Number of Participants Experiencing High Grade Immune-Mediated Adverse Events (IMAE)
ParticipantsNivolumab + Ipilimumab
Pneumonitis Grade 3-42
Nephritis and Renal Dysfunction Grade 3-41
Rash Grade 3-42
Adrenal Insufficiency Grade 3-41
Diarrhea/Colitis Grade 3-50
Hepatitis Grade 3-50
Nephritis and Renal Dysfunction Grade 50
Rash Grade 50
Hypersensitivity Grade 3-50
Adrenal Insufficiency Grade 50
Hypothyroidism/Thyroiditis Grade 3-50
Diabetes Mellitus Grade 3-50
Hyperthyroidism Grade 3-50
Hypophysitis Grade 3-50
SecondaryTime to Onset of High Grade Immune-Mediated Adverse Event (IMAE)

Time to onset is defined as the time between the day of the first dose of study treatment and the onset date of the earliest AE (Grades 3-5) in this category. All IMAEs that occurred between first dose and 100 days past last dose are recorded. IMAEs are a type of adverse event that occurs when the immune system reacts against the body's own tissues. IMAE analyses includes events, regardless of causality, which occurred during the study and follow-up. Only participants who received immune-modulating medication for treatment of the event are reported, with the exception of endocrine events, which will be included regardless of treatment since these events are often managed without immunosuppression. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose until onset of IMAE (up to approximately 15 months)
Reported as:
Median · Weeks
Time to Onset of High Grade Immune-Mediated Adverse Event (IMAE)
WeeksNivolumab + Ipilimumab
ADRENAL INSUFFICIENCY9.9 (9.9 to 9.9)
PNEUMONITIS7.29 (1.4 to 13.1)
NEPHRITIS AND RENAL DYSFUNCTION20.00 (20.0 to 20.0)
RASH29.21 (29.0 to 29.4)
SecondaryTime to Resolution of High Grade Immune-Mediated Adverse Event (IMAE)

Time to resolution of IMAEs is defined as the longest time from onset to complete resolution or improvement to the grade at baseline among all clustered AEs experienced by the participant in this category per adverse event criteria category. Events which worsened into grade 5 events (death) or have a resolution date equal to the date of death are considered unresolved. If a clustered AE is considered as unresolved, the resolution date will be censored to the last known alive date. Improvement to the grade at baseline implies that all different events in the clustered adverse event should at least have improved to the corresponding (i.e. with same preferred term) baseline grade. High grade (Grades 3 through 5) IMAEs are reported. IMAEs are graded on a scale from 1 to 5, in which Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events may require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose until resolution of IMAE (up to approximately 15 months)
Reported as:
Median · Weeks
Time to Resolution of High Grade Immune-Mediated Adverse Event (IMAE)
WeeksNivolumab + Ipilimumab
ADRENAL INSUFFICIENCY1.1 (1.1 to 1.1)
RASH10.07 (5.0 to 15.1)
SecondaryThe Number of Participants Who Received Immune-Modulating Medication

Immune modulating medications are medications entered on an immune modulating medication form or available from the most current pre-defined list of immune modulating medications. This list is revisited whenever UMC WHO releases a new version and updated accordingly.

Time frame:
From first dose up to 100 days after last dose (up to approximately 15 months)
Reported as:
Count of participants · Participants
The Number of Participants Who Received Immune-Modulating Medication
ParticipantsNivolumab + Ipilimumab
The Number of Participants Who Received Immune-Modulating Medication38
SecondaryObjective Response Rate (ORR)

Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose up to 100 days after last dose (up to approximately 15 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsNivolumab + Ipilimumab
Objective Response Rate (ORR)37.6 (27.4 to 48.8)
SecondaryTime to Response (TTR)

TTR is defined as the time from the date of first dose to the date of the first confirmed documented response (CR or PR). For the non-responders, TTR was censored at the maximum time of response + 1 day of all participants. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of CR or PR (up to approximately 15 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsNivolumab + Ipilimumab
Time to Response (TTR)2.79 (2.3 to 10.3)
SecondaryDuration of Response (DoR)

Duration of Response (DOR) is defined as the time between the date of first documented response (CR or PR) that was subsequently confirmed to the date of the first documented progression as determined using RECIST 1.1, or death due to any cause, whichever occurs first. For participants who neither progress nor die, the duration of response will be censored on the date of their last evaluable tumor assessment. For participants who start subsequent therapy before progression or die, the duration of response will be censored on the date of their last evaluable tumor assessment conducted on or prior to the initiation of the subsequent therapy. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Analysis based on Kaplan Meier estimates.

Time frame:
From first documented response (CR or PR) up to first documented progression or death due to any cause, whichever occurs first (up to approximately 3 years)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsNivolumab + Ipilimumab
Duration of Response (DoR)NA (1.3 to 9.9)

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 3 years). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 15 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + Ipilimumab11/101 (10.9%)37/101 (36.6%)80/101 (79.2%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventNivolumab + Ipilimumab
HyponatraemiaMetabolism and nutrition disorders5/101
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/101
AnaemiaBlood and lymphatic system disorders3/101
DeathGeneral disorders2/101
Renal impairmentRenal and urinary disorders2/101
DyspnoeaRespiratory, thoracic and mediastinal disorders2/101
PneumonitisRespiratory, thoracic and mediastinal disorders2/101
Acute coronary syndromeCardiac disorders1/101
Cardiac arrestCardiac disorders1/101
Myocardial infarctionCardiac disorders1/101
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNivolumab + Ipilimumab
CoughRespiratory, thoracic and mediastinal disorders25/101
PruritusSkin and subcutaneous tissue disorders21/101
AstheniaGeneral disorders19/101
PyrexiaGeneral disorders17/101
AnaemiaBlood and lymphatic system disorders14/101
Back painMusculoskeletal and connective tissue disorders13/101
DiarrhoeaGastrointestinal disorders12/101
RashSkin and subcutaneous tissue disorders12/101
NauseaGastrointestinal disorders11/101
FatigueGeneral disorders11/101

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(Years)Nivolumab + Ipilimumab
Mean56.0 ± 9.99
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + Ipilimumab
Female22
Male79
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nivolumab + Ipilimumab
Asian Indian101
08

Study locations

11 sites
  • Local Institution - 0005
    Ahmedabad, Gujarat 380054, India
  • Local Institution - 0011
    Trivandrum, Kerala 695011, India
  • Local Institution - 0013
    Mumbai, Maharashtra 400 057, India
  • Local Institution - 0001
    Mumbai, Maharashtra 400012, India
  • Local Institution - 0007
    New Delhi, National Capital Territory of Delhi 110029, India
  • Local Institution - 0006
    Bangalore, 560017, India
  • Local Institution - 0017
    Delhi, 110085, India
  • Local Institution - 0002
    Karnataka, 560027, India
  • Local Institution - 0019
    Kolkata, 711103, India
  • Local Institution - 0016
    Mumbai, 400053, India
  • Local Institution - 0012
    Pune, 411001, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jan 2024, 36 months.

Results were first posted in Jul 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 14, 2020
StartActual
Dec 17, 2020
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 4, 2024
Results first posted
Jul 11, 2025
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04513522
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Dec 17, 2020
Primary completion
Jan 4, 2024
Completion
Jan 4, 2024
Results posted
Jul 11, 2025
Last update
Jul 11, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion